8-K: LAVA Therapeutics Shareholders Approve Merger, New Directors

LAVA Therapeutics N.V. shareholders overwhelmingly approved a proposed merger with LAVA Therapeutics New Topco B.V. and the appointment of new executive and non-executive directors at an Extraordinary General Meeting.

Summary

• An Extraordinary General Meeting (EGM) of shareholders was held on November 7, 2025, with 63.45% of outstanding shares present, establishing a quorum.
• Shareholders conditionally appointed Owen Hughes as an executive director with 16,649,396 votes for, 9,304 against, and 34,501 abstentions.
• Conditional appointments of Thomas Burns (16,649,383 for), Bradley Sitko (16,647,337 for), and Maricel Montano (16,648,457 for) as non-executive directors were also approved.
• The board of directors was granted full and final discharge for their acts of management or supervision up to the EGM date, with 14,901,602 votes for, 204,004 against, and 1,587,595 abstentions.
• A conditional resolution to enter into a Dutch statutory merger (Downstream Merger) with LAVA Therapeutics New Topco B.V. was approved with 16,672,260 votes for, 12,474 against, and 8,467 abstentions.
• A conditional resolution to approve the Downstream Merger and the cancellation of all outstanding Class A shares of New TopCo following the effective time was approved with 16,672,234 votes for, 12,474 against, and 8,493 abstentions.

Sentiment

Score: 8

Explanation: Overwhelming shareholder approval for all key proposals, including a significant merger and board appointments, indicates strong internal alignment and a clear path forward for the company's strategic direction.

Positives

• All proposed resolutions, including the conditional merger and director appointments, received overwhelming shareholder approval.
• The high percentage of 'for' votes for the merger (over 99% of votes cast) indicates strong shareholder confidence in the strategic direction.
• The appointment of new executive and non-executive directors strengthens the company's leadership and governance structure.

Negatives

• A notable number of votes (204,004 against and 1,587,595 abstentions) were cast against or abstained from the resolution to grant full and final discharge to the board of directors, though the resolution still passed.

Risks

• The resolutions for the merger and director appointments are conditional, implying that certain conditions must be met for them to become effective.
• Investors are urged to read the Tender Offer Statement on Schedule TO and the Solicitation/Recommendation Statement on Schedule 14D-9 for important information, which would include detailed risks related to the tender offer and merger.

Future Outlook

The overwhelming shareholder approval of the conditional Downstream Merger with LAVA Therapeutics New Topco B.V. indicates a clear strategic path towards the completion of this corporate restructuring, subject to the fulfillment of stated conditions.

Industry Context

This announcement primarily concerns a company-specific corporate restructuring and governance update. Without further details on the strategic rationale for the merger, which would typically be found in related tender offer documents, it is difficult to provide a broad industry context from this filing alone.

Management Changes

Corporate Governance

Related Party Transactions

• The Downstream Merger involves LAVA Therapeutics New Topco B.V. issuing Class B shares to XOMA Royalty Corporation (Buyer) and Class A shares to other LAVA Therapeutics N.V. shareholders. This differentiated share issuance structure for a specific buyer in the context of a tender offer could be considered a related party transaction depending on XOMA's prior relationship with LAVA.

Stakeholder Impact

• Shareholders: Will exchange their ordinary shares in LAVA Therapeutics N.V. for Class A or Class B shares in LAVA Therapeutics New Topco B.V. as part of the merger consideration.
• Management/Board: New executive and non-executive directors have been conditionally appointed, and existing board members have been discharged.
• Company: LAVA Therapeutics N.V. will cease to exist as a separate entity, merging into LAVA Therapeutics New Topco B.V.

Next Steps

• Completion of the conditional Dutch statutory merger (Downstream Merger) with LAVA Therapeutics New Topco B.V.
• Issuance of Class A and Class B shares by New Topco as part of the merger consideration.
• Cancellation of all outstanding Class A shares of New TopCo following the effective time of the Downstream Merger.

Key Dates

Recommendation

Shareholders have overwhelmingly approved the merger with LAVA Therapeutics New Topco B.V. and the associated tender offer. This indicates a clear path towards the completion of the transaction. Investors should hold their shares to participate in the merger and receive the consideration as outlined in the tender offer documents. Further action would depend on the specific terms of the tender offer and individual investment strategies.

Keywords

LAVA Therapeutics, LVTX, SEC filing, 8-K, EGM, shareholder meeting, merger, corporate governance, director appointments, tender offer, XOMA Royalty Corporation